Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis

NCT00677092 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00677092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00677092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
July 31, 2009
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nephrogenic systemic fibrosis